share_log

RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $32 Price Target

Benzinga ·  Jul 10 09:31

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $32 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment